Medicine, Hematology Oncology Division

Fingerprint Dive into the research topics where Medicine, Hematology Oncology Division is active. These topic labels come from the works of this organization's members. Together they form a unique fingerprint.

Neoplasms Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Breast Neoplasms Medicine & Life Sciences
Survival Medicine & Life Sciences
Drug Therapy Medicine & Life Sciences
Prostatic Neoplasms Medicine & Life Sciences
Acute Myeloid Leukemia Medicine & Life Sciences
Leukemia, Myelogenous, Chronic, BCR-ABL Positive Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Profiles

No photo of Kehinde Adekola

Kehinde Adekola

Person: Academic

20122023
No photo of Mark Agulnik

Mark Agulnik

Person: Academic

20012023
No photo of Jessica K Altman

Jessica K Altman

Person: Academic

20052024

Research Output 1956 2020

5 Citations (Scopus)

Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer

Formisano, L., Lu, Y., Servetto, A., Hanker, A. B., Jansen, V. M., Bauer, J. A., Sudhan, D. R., Guerrero-Zotano, A. L., Croessmann, S., Guo, Y., Ericsson, P. G., Lee, K. M., Nixon, M. J., Schwarz, L. J., Sanders, M. E., Dugger, T. C., Cruz, M. R., Behdad, A., Cristofanilli, M., Bardia, A. & 11 others, O’Shaughnessy, J., Nagy, R. J., Lanman, R. B., Solovieff, N., He, W., Miller, M., Su, F., Shyr, Y., Mayer, I. A., Balko, J. M. & Arteaga, C. L., Dec 1 2019, In : Nature communications. 10, 1, 1373.

Research output: Contribution to journal › Article

Open Access
breast
inhibitors
cancer
Breast Neoplasms
Protein-Tyrosine Kinases

A Case of Metastatic Biliary Tract Cancer Diagnosed Through Identification of an IDH1 Mutation

Kamath, S. D., Lin, X. & Kalyan, A., Feb 1 2019, In : Oncologist. 24, 2, p. 151-156 6 p.

Research output: Contribution to journal › Article

Biliary Tract Neoplasms
Mutation
Adenocarcinoma
Neoplasms
Paraffin

A case report of clonal EBV-like memory CD4+ T cell activation in fatal checkpoint inhibitor-induced encephalitis

Johnson, D. B., McDonnell, W. J., Gonzalez-Ericsson, P. I., Al-Rohil, R. N., Mobley, B. C., Salem, J. E., Wang, D. Y., Sanchez, V., Wang, Y., Chastain, C. A., Barker, K., Liang, Y., Warren, S., Beechem, J. M., Menzies, A. M., Tio, M., Long, G. V., Cohen, J. V., Guidon, A. C., O’Hare, M. & 13 others, Chandra, S., Chowdhary, A., Lebrun-Vignes, B., Goldinger, S. M., Rushing, E. J., Buchbinder, E. I., Mallal, S. A., Shi, C., Xu, Y., Moslehi, J. J., Sanders, M. E., Sosman, J. A. & Balko, J. M., Aug 1 2019, In : Nature Medicine. 25, 8, p. 1243-1250 8 p.

Research output: Contribution to journal › Letter

T-cells
Encephalitis
Human Herpesvirus 4
Chemical activation
T-Cell Antigen Receptor

Grants 1996 2027

Prot #ADP-0044-002: A Phase 2 Single Arm Open-Label Clinical Trial of ADP-A2M4 SPEAR™ T cells in Subjects with Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma

Agulnik, M.

ICON plc, Adaptimmune LLC

11/26/19 → 11/26/22

Project: Research project

Prot #D933RC00001: A Phase III, Randomized, Open-Label, Multi-Center, Global Study to Determine the Efficacy and Safety of Durvalumab in Combination with Gemcitabine+Cisplatin for Neoadjuvant Treatment Followed by Durvalumab Alone for Adjuvant Treatment i

VanderWeele, D. J.

AstraZeneca Pharmaceuticals LP

11/20/19 → 11/20/22

Project: Research project

Prot #PANC003: A Phase III Multicenter Open-Label Randomized Trial to Evaluate Efficacy and Safety of FOLFIRINOX (FFX) versus Combination of CPI-613 with modified FOLFIRINOX (mFFX) in Patients with Metastatic Adenocarcinoma of the Pancreas

Benson III, A. B.

Covance Inc., Rafael Pharmaceuticals, Inc.

10/25/19 → 10/25/22

Project: Research project